Comparative Pharmacology
Head-to-head clinical analysis: ALEVE PM versus EYDENZELT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE PM versus EYDENZELT.
ALEVE PM vs EYDENZELT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenhydramine is a histamine H1 receptor antagonist that competes with histamine for binding at H1 receptor sites, reducing symptoms of allergic reactions and causing sedation. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, decreasing synthesis of prostaglandins, which reduces pain and inflammation.
EYDENZELT (bexarotene) is a retinoid that selectively binds to and activates retinoid X receptors (RXRs), which regulate gene expression involved in cell differentiation, proliferation, and apoptosis. It induces apoptosis and inhibits cell growth in malignant T-cells.
1 tablet (220 mg naproxen sodium / 25 mg diphenhydramine HCl) orally at bedtime as needed. Maximum: 2 tablets in 24 hours.
1 mg subcutaneously once weekly.
None Documented
None Documented
Naproxen: 12-17 hours (mean 13.6 hours); sufficient for twice-daily dosing; prolonged in renal impairment. Diphenhydramine: 2.4-9.3 hours (mean 5.5 hours); longer in elderly, hepatic impairment.
Terminal elimination half-life is approximately 12-14 hours, allowing once-daily dosing with steady-state reached within 3-5 days.
Naproxen: renal (95% as unchanged drug and metabolites, primarily as naproxen and 6-O-desmethyl naproxen). Diphenhydramine: renal (50-60% as unchanged drug and metabolites, primarily as diphenhydramine and nor diphenhydramine); small amounts in feces.
Primarily renal excretion as unchanged drug (approximately 70-80%) and minor fecal elimination (≤10%). Biliary excretion is negligible.
Category C
Category C
NSAID/Antihistamine Combination
NSAID